Lexicon Pharma (LXRX): Sotagliflozin Results Offer Hint Into 2018 FDA Review - Wedbush
Tweet Send to a Friend
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) after Sotagliflozin achieved statistical significance ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE